|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
6.000 0.000 (0.000%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 410,499 | 25.598% | 716,912 | 533,881 | 354,555 | 253,542 |
| Cost of Sales | (105,006) | 14.796% | (210,878) | (142,131) | (107,115) | (86,549) |
| Gross Profit | 305,493 | 29.796% | 506,034 | 391,750 | 247,440 | 166,993 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 6,483 | 588.217% | 4,879 | 3,923 | 9,812 | (76,604) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (9,085) | 82.320% | (10,027) | (14,770) | (402) | 87 | |
| Profit / (Loss) before Taxation | (47,077) | -75.143% | (380,156) | (601,353) | (545,643) | (476,691) | |
| Taxation | (3,596) | 756.190% | (2,796) | (804) | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 1 | 212 | 67 | 48,600 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (50,673) | -73.303% | (382,951) | (601,945) | (545,576) | (428,091) | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 49,280 | 19.728% | 89,686 | 53,972 | 26,919 | 16,788 |
| Depreciation & Amortisation | 85,461 | 1.663% | 189,982 | 174,099 | 128,097 | 43,367 |
| Directors' Emoluments | -- | -- | 6,331 | 3,672 | 7,041 | 125,428 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -13.000 | -72.917% | -96.000 | -158.000 | -151.000 | -- |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.192) | (0.796) | (1.009) | -- |
| NBV per share ($) | 1.852 | -- | 1.968 | 2.870 | -- | -- |
| Remarks: | Real time quote last updated: 22/11/2024 08:27 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -50,673,000 |
| %Change | -73.303% |
| EPS / (LPS) | RMB -0.130 |
| NBV Per Share (¥) | RMB 1.852 |